It has been a very rough start to 2016 on the capital markets with the Dow Jones Industrial average shedding almost 3 percent of its value in the wake of geopolitical and macroeconomic uncertainties – but this hasn't seemed to deter both public and private biotech companies from their plans to boost their cash balances.